Overview

A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021

Status:
Completed
Trial end date:
2013-07-23
Target enrollment:
Participant gender:
Summary
This study is a 1-year open label extension study to collect long term efficacy and safety data from patients who have completed approximately 2 years of dosing in Study CL0600-021.
Phase:
Phase 3
Details
Lead Sponsor:
Shire
Treatments:
Teduglutide